Challenges in IBD Research: Novel Technologies

Author:

Dhyani Manish1,Joshi Nitin2,Bemelman Willem A3,Gee Michael S4,Yajnik Vijay5,D’Hoore André6,Traverso Giovanni7,Donowitz Mark8,Mostoslavsky Gustavo9,Lu Timothy K10,Lineberry Neil5,Niessen Heiko G11,Peer Dan12,Braun Jonathan13,Delaney Conor P14,Dubinsky Marla C15,Guillory Ashley N16,Pereira Maria17,Shtraizent Nataly18,Honig Gerard18,Polk David Brent1920,Hurtado-Lorenzo Andrés18,Karp Jeffrey M21,Michelassi Fabrizio22

Affiliation:

1. Lahey Hospital & Medical Center, Burlington, Massachusetts

2. Brigham and Women’s Hospital, Boston, Massachusetts

3. Academic Medical Centre, Amsterdam, Netherlands

4. Massachusetts General Hospital, Boston, Massachusetts

5. Takeda Pharmaceutical Company, Boston, Massachusetts

6. University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium

7. Brigham and Women’s Hospital, Harvard Medical School and Massachusetts Institute of Technology, Boston, Massachusetts

8. Johns Hopkins University School of Medicine, Baltimore, Maryland

9. Boston University School of Medicine, Boston, Massachusetts

10. Massachusetts Institute of Technology, Cambridge, Massachusetts

11. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

12. School of Molecular Cell Biology and Biotechnology, Tel Aviv University, Tel Aviv, Israel

13. Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai, Los Angeles, California

14. Cleveland Clinic Foundation, Cleveland, Ohio

15. Icahn School of Medicine at Mount Sinai, New York, New York

16. University of Texas Medical Branch, Galveston, Texas

17. Gecko Biomedical, Paris, France

18. Crohn’s & Colitis Foundation, New York, New York

19. Department of Biochemistry and Molecular Biology, University of Southern California

20. Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, California

21. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Broad Institute and Harvard Stem Cell Institute, Boston, Massachusetts

22. New York-Presbyterian Hospital and Weill Cornell School of Medicine, New York, New York

Abstract

This section is focused on prioritizing unmet clinical needs that will benefit from novel technologies applied to non-invasive detection and monitoring of active inflammation and assessment of treatment response, mucosal targeted drug delivery systems, and prevention of post-operative septic complications and treatment of fistulizing complications.

Funder

Crohn’s & Colitis Foundation

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3